Cutaneous leishmaniasis is a parasitic skin disease caused by protozoa of the genus Leishmania, transmitted through the bite of tiny female sand flies. It produces skin ulcers that can take months to heal and often leave permanent scars, affecting an estimated 600,000 to one million people each year across tropical and subtropical regions. Despite being one of the most common neglected tropical diseases on the planet, it remains poorly understood by the general public and dramatically underfunded relative to its burden. The biology behind the infection, from the cunning way the parasite hijacks immune cells to the surprising role sand fly saliva plays in making things worse, turns out to be far more complex than a simple bug bite gone bad.
How Sand Flies Deliver More Than Just a Parasite
The infection begins when a female phlebotomine sand fly, an insect roughly a third the size of a mosquito, bites exposed skin to feed on blood. Along with the Leishmania parasites, the fly injects saliva loaded with bioactive molecules that have anticoagulant, anti-inflammatory, and blood-vessel-dilating properties, all evolved to help the fly feed more efficiently.1PubMed. Dr. Jekyll and Mr. Hyde in sand fly saliva Those salivary compounds do not just help the fly. Research in mice has shown that Leishmania parasites co-injected with sand fly salivary gland extracts produced larger lesions containing roughly a thousand times more parasites than controls that received parasites alone.2PubMed Central. Sand fly saliva enhances Leishmania amazonensis infection by modulating interleukin-10 production The mechanism appears to involve a surge in interleukin-10, an immune-dampening signal that suppresses the very defenses the body needs to fight off the infection early.
There is a flip side. Some salivary components, when encountered by the immune system before a real infection, can prime a protective response. This has led researchers to explore sand fly saliva proteins as potential vaccine candidates, an idea that flips the parasite’s own trick against it.3PubMed. Dr. Jekyll and Mr. Hyde in sand fly saliva
What Happens Once the Parasite Reaches Your Cells
After being deposited in the skin, Leishmania parasites are engulfed by macrophages, the immune cells whose job is to swallow and destroy invaders. In most infections, that would be the end of the story. Leishmania, however, has evolved to not only survive inside macrophages but to thrive there. The parasite’s two life stages use different strategies to get in. The form transmitted by the sand fly enters macrophages through cholesterol-rich membrane domains and deliberately delays the cell’s normal killing machinery. The form that multiplies inside the body takes a different entry route and manipulates the timing of the cell’s internal digestion process in another way.4PubMed Central. Stage-specific pathways of Leishmania infantum chagasi entry and phagosome maturation in macrophages Either way, the result is the same: the parasite converts the very cell that was supposed to kill it into a safe house where it can reproduce.
The Immune Response That Decides Whether You Heal
Whether a cutaneous leishmaniasis lesion resolves on its own or persists for months (sometimes years) depends heavily on which arm of the immune system takes the lead. Studies comparing patients whose lesions healed with those whose lesions did not have found a consistent pattern. People who healed produced higher levels of interferon-gamma and interleukin-12, signals associated with a cell-killing immune pathway. People whose lesions persisted produced more interleukin-4, interleukin-5, and interleukin-10, signals that dampen that cell-killing response and favor a less effective antibody-based reaction.5PubMed Central. Comparison of Th1 and Th2 responses in non-healing and healing patients with cutaneous leishmaniasis During active disease, both pathways are firing simultaneously, creating a tug-of-war. Clinical cure seems to happen when the cell-killing pathway wins out and the dampening signals fade.6PubMed. Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production
This immune balancing act also explains why the disease looks so different from person to person. A healthy adult with a robust cell-killing response may develop a single ulcer that heals in a few months. Someone whose immune system tilts the other way, or who is immunocompromised, can develop dozens or even hundreds of lesions.
Old World and New World Forms
Cutaneous leishmaniasis is not one disease so much as a family of related conditions caused by different Leishmania species on different continents. “Old World” forms, found in parts of the Middle East, North Africa, Central Asia, and the Mediterranean basin, are typically caused by species like L. major and L. tropica. These lesions can sometimes heal spontaneously without treatment. “New World” forms, found across Central and South America, are caused by species in the Leishmania Viannia subgenus and others like L. mexicana and L. amazonensis. Most New World cases require systemic treatment, partly to speed healing but also to prevent a more dangerous complication: spread to the mucous membranes of the nose and mouth.7PubMed. Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis
The animal reservoirs also differ by region. In many Old World settings, rodents are the primary hosts maintaining the parasite in nature. In the Americas, the reservoir picture is more complicated, involving forest-dwelling mammals. In some areas, such as Sri Lanka, researchers have found Leishmania parasites in dogs, though whether dogs serve as true reservoirs there remains unresolved.8PubMed. Cutaneous leishmaniasis in Sri Lanka: a study of possible animal reservoirs
When Cutaneous Disease Spreads to the Mucous Membranes
Mucocutaneous leishmaniasis is the most feared progression of the cutaneous form. It occurs almost exclusively with certain New World species, particularly L. braziliensis, and involves the parasite migrating from the original skin lesion to the nose, mouth, or throat, where it can destroy tissue and cause severe disfigurement. A large case-comparison study of more than 2,800 patients in southeastern Brazil identified several factors that raised the risk. Men were about 1.7 times more likely than women to develop mucosal disease. People older than 22 had roughly double the risk of younger patients. Severe malnutrition raised the risk almost fourfold, and having the skin disease for more than four months before treatment also increased the odds nearly fourfold.9Transactions of The Royal Society of Tropical Medicine and Hygiene. Risk factors for mucosal manifestation of American cutaneous leishmaniasis The combination of older age and poor nutrition was especially dangerous, with risk climbing steeply when both were present. This is one of the strongest arguments for treating New World cutaneous leishmaniasis promptly rather than waiting for spontaneous healing.
Diagnosing Cutaneous Leishmaniasis
Getting a definitive diagnosis can be surprisingly tricky. A painless or slow-healing skin ulcer in someone who has traveled to or lives in an endemic area raises suspicion, but the clinical picture overlaps with bacterial infections, fungal diseases, skin cancer, and other tropical conditions. The traditional approach combines microscopy, where a tissue sample is smeared on a slide and examined for parasites, with culture, where a sample is grown in a lab medium. Microscopy alone picks up roughly three-quarters of confirmed cases, and culture alone catches about half. Combined, they reach about 83% sensitivity.10PubMed Central. Comparison of PCR assays for diagnosis of cutaneous leishmaniasis
Molecular tests have substantially improved accuracy. A systematic review and meta-analysis found that PCR performed on skin smears had a pooled sensitivity around 95%.11PLoS Neglected Tropical Diseases. Test accuracy of polymerase chain reaction methods against conventional diagnostic techniques for Cutaneous Leishmaniasis (CL) in patients with clinical or epidemiological suspicion of CL: Systematic review and meta-analysis In another study comparing methods head to head, PCR detected about 94% of cases versus 77% for microscopy and 51% for culture.12PubMed Central. Comparison of Three Methods for Diagnosis of Cutaneous Leishmaniasis PCR also identifies the Leishmania species, which matters for choosing treatment and assessing mucosal risk.
The challenge is that PCR requires lab equipment, trained personnel, and electricity, all of which are scarce in many endemic areas. Rapid diagnostic tests based on antigen detection are being developed for field use. One such test evaluated in Morocco showed specificity above 90% but sensitivity of only about 64 to 83%, depending on how the sample was collected.13PubMed Central. Accuracy of a Rapid Diagnostic Test Based on Antigen Detection for the Diagnosis of Cutaneous Leishmaniasis in Patients with Suggestive Skin Lesions in Morocco A positive result on the rapid test can be treated with confidence, but a negative result still needs follow-up with microscopy or PCR. Newer field-applicable molecular tools, including isothermal amplification methods that do not require a thermal cycler, have shown excellent agreement with PCR in early testing and could eventually bridge the gap between lab accuracy and field practicality.14PLOS Neglected Tropical Diseases. An Innovative Field-Applicable Molecular Test to Diagnose Cutaneous Leishmania Viannia spp. Infections
Treatment Options and Their Trade-Offs
The mainstay of systemic treatment for decades has been pentavalent antimonial compounds, injected either into the bloodstream or directly into the lesion. Systemic antimonials work, but they come with a long list of side effects including joint pain, muscle pain, and blood-count changes, with evidence suggesting these side effects are dose-dependent.15PubMed. Antimony in plasma and skin of patients with cutaneous leishmaniasis–relationship with side effects after treatment with meglumine antimoniate Injecting the drug directly into the lesion largely avoids systemic toxicity; a systematic review of that approach found no reported systemic side effects, with only local reactions like pain and swelling at the injection site.16PLoS ONE. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review
Thermotherapy, which uses a device to apply controlled heat directly to the lesion, has emerged as a practical alternative. A multicenter trial found that a single session of thermotherapy cured about 58% of patients with New World cutaneous leishmaniasis at three months. When that single heat session was combined with a short course of oral miltefosine, the cure rate climbed to about 80%.17PLoS Neglected Tropical Diseases. A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World A systematic review confirmed that single-dose thermotherapy performed comparably to a full 28-day course of miltefosine alone, with fewer side effects, and that the combination outperformed thermotherapy by itself.18Dermis. Effectiveness of Thermotherapy in Cutaneous Leishmaniasis: Systematic Review The appeal is obvious: a one-time clinic visit with a heat device plus a shorter drug course is far more practical in remote endemic settings than weeks of daily injections.
The Growing Problem of Drug Resistance
Antimonial drugs have been used for more than a century, and resistance has become a serious obstacle in some regions, particularly South Asia. Resistant parasites accumulate less of the drug inside their cells, partly because they reduce the activity of the transporter that lets the drug in. They also ramp up their internal defenses against the oxidative stress that antimonials cause, producing higher levels of thiol compounds that neutralize the drug’s effects.19PubMed Central. Insights into drug resistance in Leishmania: Mechanisms, therapeutics, and clinical case studies On top of that, the parasites use specialized pump proteins to actively eject drug molecules. The resistance machinery is not a single trick but a layered defense involving reduced drug uptake, enhanced detoxification, and active drug export.20PubMed Central. Antimony resistance in leishmania, focusing on experimental research This multi-pronged resistance makes it difficult to design simple workarounds, and it is one of the driving forces behind the search for new drugs and combination regimens.
HIV Co-Infection Changes the Rules
In people living with HIV, cutaneous leishmaniasis can behave in dramatically atypical ways. The weakened cellular immune response that HIV causes removes exactly the defense the body relies on to contain Leishmania. Case reports describe HIV-positive patients developing more than 200 skin lesions, including lesion types and distributions that would be extremely unusual in someone with an intact immune system.21PubMed. Diffuse cutaneous leishmaniasis: Co-infection with human immunodeficiency virus (HIV) The parasites also lose their usual tissue preferences. A species that normally causes only skin disease may spread to the viscera, and mucosal involvement becomes more common regardless of the Leishmania species involved.22PLoS Neglected Tropical Diseases. PKDL and Other Dermal Lesions in HIV Co-infected Patients with Leishmaniasis: Review of Clinical Presentation in Relation to Immune Responses The two infections compound each other: Leishmania activates HIV replication in co-infected cells, while HIV weakens the immune control of Leishmania. In areas where both infections are endemic, particularly East Africa and parts of South America, co-infection is a growing clinical challenge.
Scars, Stigma, and Lasting Social Harm
Even after the parasite is cleared, cutaneous leishmaniasis leaves a mark. The permanent scars, particularly on the face and hands, create a social burden that outlasts the medical one. Research across multiple countries has found that the disease is a source of psychological suffering, stigmatization, and reduced quality of life.23PubMed Central. Cutaneous leishmaniasis: A neglected disfiguring disease for women The impact falls disproportionately on women. Studies in Morocco and Afghanistan have documented that facial scars from cutaneous leishmaniasis act as a barrier to marriage for women, with families reporting they would not allow their sons to marry a woman with visible scars.24PLOS Neglected Tropical Diseases. Stigma associated with cutaneous and mucocutaneous leishmaniasis: A systematic review Interestingly, the same research noted that existing scars were not cited as grounds for divorce, only as a reason to reject a prospective bride, suggesting the stigma operates more as a social screening mechanism than as a cause of relationship breakdown.
The wound-healing process itself appears to be partly under genetic control. Mouse studies have shown that animals genetically predisposed to resist Leishmania also expressed higher levels of tissue repair genes, produced more organized collagen in healing wounds, and healed experimental skin injuries faster than their susceptible counterparts.25PubMed Central. The wound repair response controls outcome to cutaneous leishmaniasis If similar genetic variation operates in humans, it could help explain why some people are left with barely visible marks while others develop raised, disfiguring scars from similar-sized lesions.
The Economic Weight on Families
Cutaneous leishmaniasis hits hardest in rural, low-income communities, and the financial toll extends well beyond medical bills. A study in Brazil found that the average total cost of one treatment cycle per patient was about $117, but indirect costs from lost workdays averaged around $160 per patient. More strikingly, catastrophic health expenditure, defined as out-of-pocket spending that pushes a family into financial hardship, affected about 43% of families dealing with the disease.26PLOS Neglected Tropical Diseases. The burden of out-of-pocket and indirect costs of cutaneous leishmaniasis patients in Minas Gerais, Brazil Transportation and food costs during treatment were among the largest expenses, reflecting the reality that many patients must travel long distances to reach clinics capable of diagnosing and treating the disease. In Sri Lanka, total household economic losses from a single case averaged about 5% of annual household income and over 20% of per capita income.27PubMed Central. The Economic Impact of Cutaneous Leishmaniasis in Sri Lanka
Climate Change and Shifting Sand Fly Ranges
Sand flies are sensitive to temperature and humidity, which means a warming climate has direct implications for where cutaneous leishmaniasis shows up. Modeling studies project that in the coastal areas of the eastern Mediterranean and the mid-elevation zones of western Iran and southeastern Turkey, conditions for both the sand fly vectors and the Leishmania parasites they carry will become more favorable through the mid and late 21st century.28Theoretical and Applied Climatology. The potential effects of climate change on the climatic suitability patterns of the Western Asian vectors and parasites of cutaneous leishmaniasis in the mid- and late twenty-first century In Morocco, similar modeling predicts that Phlebotomus sergenti, the sand fly species that transmits L. tropica, will continue to find suitable habitat and may increase in abundance, raising transmission risk.29PubMed. Climate Change Influences on the Potential Distribution of the Sand Fly Phlebotomus sergenti, Vector of Leishmania tropica in Morocco
The picture is not uniformly worse everywhere. The same models suggest that in parts of Iraq, northern Saudi Arabia, Kuwait, and interior regions of western Asia, conditions may become too hot and dry even for sand flies, potentially reducing transmission in areas where it is currently high. The net effect, though, is a geographic reshuffling that could bring cutaneous leishmaniasis into densely populated areas where it has not historically been a major problem, catching health systems unprepared.
Vector Control That Already Exists
While a specific anti-sand-fly program would be ideal, the reality in most endemic areas is that sand fly control piggybacks on malaria prevention. Insecticide-treated bed nets and indoor residual spraying, both deployed primarily against mosquitoes, also kill sand flies. A systematic review found that insecticide-impregnated nets produced sand fly mortality as high as 75%, with effects lasting over a year.30PubMed Central. Efficacy and community-effectiveness of insecticide treated nets for the control of visceral leishmaniasis: A systematic review In central Mali, villages that received bed nets and indoor spraying for malaria control saw substantial drops in both sand fly density and human Leishmania infection rates compared to historical data.31PubMed Central. Impact of insecticide-treated bednets and indoor residual spraying in controlling populations of Phlebotomus duboscqi, the vector of Leishmania major in Central Mali This dual benefit makes a strong case for maintaining or expanding bed net programs in areas where both diseases co-occur, even as malaria funding faces pressure.
Why There Is Still No Human Vaccine
The immunology of leishmaniasis would seem to favor vaccine development. People who recover from the disease develop lasting immunity, and researchers understand fairly well which immune signals are needed for protection. Yet no approved human vaccine exists. Strategies tested so far include killed whole parasites, weakened live parasites, recombinant proteins, and DNA-based approaches. The fundamental challenge is twofold. First, Leishmania species vary enormously in their surface proteins, so a vaccine that works against one species in one region may not work against a different species elsewhere. Second, generating the durable, cell-killing-type immune response needed for protection has proven difficult to achieve reliably in trials.32PubMed Central. Advances in Leishmania Vaccines: Current Development and Future Prospects With drug resistance growing and vector control limited, the need for an effective vaccine is becoming more pressing, but the timeline remains uncertain.33PubMed Central. Cutaneous Leishmaniasis: Update on Vaccine Development
An Ancient Disease With Modern Consequences
Cutaneous leishmaniasis is often described as a disease of poverty, but it is also a disease of deep history. Paleoparasitological studies have found Leishmania DNA in Egyptian mummies dating back more than 4,000 years, and in remains from northern Sudan dating to around 1500 BCE.34FEMS Immunology & Medical Microbiology. Leishmania: origin, evolution and future since the Precambrian In Peru, lytic bone lesions on pre-Columbian skulls are consistent with mucosal leishmaniasis, and immunohistological examination of a mummy of a six-year-old girl dated to around 800 BCE revealed macrophages containing Leishmania parasites, establishing that the disease existed in the Americas long before European contact. Ancient documents and archaeological evidence confirm that leishmaniasis was already widespread in antiquity across both hemispheres.35PubMed Central. The history of leishmaniasis The parasite’s relationship with humans, in other words, is not a modern accident of deforestation or urbanization. It is a co-evolutionary story stretching back millennia, one that our species has not yet figured out how to end.